Addendum
Abemaciclib (breast cancer; adjuvant treatment) –Addendum to Project A26-17
Report documents
-
Addendum
Abemaciclib (breast cancer; adjuvant treatment) –Addendum to Project A26-17
Dossier assessment
Indication:
Adjuvant treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive early breast cancer at high risk of recurrence
Result of dossier assessment:
- Premenopausal women: unchanged after addendum: added benefit not proven
- Postmenopausal women: unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
20-08-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-83
- Commission
- Commission awarded on 08.07.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-83
Connected Projects
-
Dossier assessment
Abemaciclib (breast cancer; adjuvant treatment) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed